American Heart Journal
Volume 153, Issue 1 , Pages 82.e1-82.e11 , January 2007

Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)

  • Gregg C. Fonarow, MD

      Affiliations

    • Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Gregg C Fonarow, MD, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, 10833 LeConte Avenue, Room 47-123 CHS, Los Angeles, CA 90095-1679.
    • ,
  • William T. Abraham, MD

      Affiliations

    • Division of Cardiology, Ohio State University, Columbus, OH
    • ,
  • Nancy M. Albert, RN, PhD

      Affiliations

    • Division of Nursing and George M and Linda H Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Wendy Gattis Stough, PharmD

      Affiliations

    • Department of Medicine, Duke University Medical Center, Durham, NC
    • Department of Clinical Research, Campbell University School of Pharmacy, Research Triangle Park, NC
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, IL
    • ,
  • Barry H. Greenberg, MD

      Affiliations

    • Department of Medicine, USCD Medical Center-Hillcrest, University of California, San Diego, CA
    • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, NC
    • ,
  • Jie Lena Sun, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Clyde Yancy, MD

      Affiliations

    • Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX
    • ,
  • James B. Young, MD

      Affiliations

    • Department of Cardiovascular Medicine, Heart Failure Section, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • on behalf of the OPTIMIZE-HF Investigators and Coordinators

Received 1 August 2006 ,Accepted 11 October 2006.

References 

  1. American Heart Association . Heart disease and stroke statistics—2006 update. Dallas (TX): American Heart Association; 2006;
  2. CIBIS-II Investigators . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  3. MERIT-HF Investigators . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  4. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  5. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Website. Available at: http://www.acc.org/qualityandscience/clinical/guidelines/failure/update/index.pdf2005;
  6. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J. 1999;20:1182–1190
  7. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  8. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819–822
  9. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43–51
  10. Bonow RO, Bennett S, Casey DE, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2005;46:1144–1178
  11. Gattis WA, O'Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol. 2004;93:74–76
  12. Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534–1541
  13. Adams KF, Lindenfeld J, Arnold JMO, et al. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–e122
  14. O'Connor C, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2006;47(Suppl A):83A
  15. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429–1435
  16. SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293–302
  17. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240–1247
  18. Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 2000;85:10A–17A
  19. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997;30:725–732
  20. O'Connor CM, Stough WG, Gallup DS, et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11:200–205
  21. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10:460–466
  22. The ESCAPE Investigators and ESCAPE Study Coordinators . Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625–1633
  23. Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289:712–718

 The OPTIMIZE-HF registry is registered: http://www.clinicaltrials.gov, study number NCT00344513 and was funded by GlaxoSmithKline.

PII: S0002-8703(06)00892-1

doi: 10.1016/j.ahj.2006.10.008

American Heart Journal
Volume 153, Issue 1 , Pages 82.e1-82.e11 , January 2007

Article Tools

* Image Usage & Resolution